Recorded device evidence

ADVIA CENTAUR VITAMIN B12 MASTER CURVE MATERIAL, TOTAL HCG MASTER CURVE MATERIAL, AND TESTOSTERONE MASTER CURVE MATERIAL (K140505): indications, design and recorded evidence

The acquired K140505 file contains product-specific indications and users, design and operating principle, non-clinical evidence actually described sections. Compare these dated manufacturer statements with your own indication and design before commissioning evidence work. They describe this submission; they do not prescribe your testing, validate performance independently or establish a suitable predicate.

Evidence retrieved 2026-10-07. Source versions and topic-specific limits are listed below.

Computed exact-code research

This decision beside its recorded product-code cohort

The 2021–2025 complete-year cohort contains 0 selected decisions under primary code JJX. 0 have valid reported receipt/decision pairs; 0 pairs are missing or invalid.

No quartiles are displayed: this complete-year cohort has fewer than 20 valid pairs.

The table shows the named decision and up to four latest exact-code research records through 2026-09-27. It can include partial-year records outside the complete-year cohort. The quartiles above use the full stated cohort, not this displayed selection.

Research recordRecorded deviceReceipt → decisionCalendar elapsed daysRecorded submission type
K140505 ↗ · this pageADVIA CENTAUR VITAMIN B12 MASTER CURVE MATERIAL, TOTAL HCG MASTER CURVE MATERIAL, AND TESTOSTERONE MASTER CURVE MATERIAL2014-02-27 → 2014-03-3132Abbreviated
K170678 ↗Beta-CrossLaps CalCheck 52017-03-06 → 2017-04-0429Traditional
K162173 ↗Elecsys CYFRA 21-1 CalCheck 52016-08-03 → 2017-01-12162Traditional
K162514 ↗Multichem A1c2016-09-08 → 2016-10-2648Abbreviated
K161874 ↗Audit MicroControls Linearity DROP LQ Blood Glucose2016-07-08 → 2016-08-1033Traditional

Use this comparison: select a record to investigate, read its actual indications and design, and document differences. A shared code or elapsed period cannot establish its relevance to your device.

Calendar elapsed days are not active FDA review time, a promised schedule or a success probability. The selection includes only the stated recorded decisions, not all applications. Latest records can postdate the named historical decision and are contextual research, not its predicates. Shared codes, summaries and observed records do not prove equivalence, current market availability, buyer applicability or predicate suitability.

Calculation, selection and source versions

Reuse the complete-endpoint exact-primary-code, documented SE-decision cohort and its stated cutoff/window. Retain its type-7 quartiles only when at least 20 valid date pairs are present. Independently subtract the named official record’s receipt date from its decision date; missing or negative pairs remain unknown. Show up to four latest exact-code research records, excluding the named ID. Parent analysis hash, source snapshots and calculation versions are retained.

Calculation: fda-named-decision-cohort-context-1; cutoff 2026-09-27; 0 parent records excluded; units record counts; calendar elapsed days.

Source snapshots: 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002.

Read beyond the decision row

Recorded evidence and differences to investigate

The summary is manufacturer-submitted context hosted by FDA. Negative/no-study statements are preserved. Evidence themes are not binding legal requirements.

Short opening excerpts identify the source sections. Read the linked original for the full study context, negative statements, tables and limitations. Public quotations are limited to 120 words per acquired summary; the internal evidence packet retains exact section ranges for review.

Indications and users

K140505 · PDF page 2 ↗ Source 2

Thd             AD VIA             Centaur® 'Vitamin                     B 12        (VB  12)           Master         Curve
                                                                                                                                                 Material           is for    in   vitro diagnostic             use        in the         verification           of
                                                                                                                                                 calibration        and           reportable       range       of the        ADVIA            Centaur      VB   12
                                                                                                                                                 assay.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

Design and operating principle

K140505 · PDF page 1 ↗ Source 3

ADVIA       Centauro          Vitamin    81 2        Master       Curve       Material         is        an
                                                                                                                                                                             in        vitro    diagnostic   product        containing   various    levels      of vitamin
                                                                                                                                                                              B12     in buffered          human            serum       albumin       with    sodium          azide      (0.2%)
                                                                                                                                                                             and      preservatives.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

Non-clinical evidence actually described

K140505 · PDF page 9 ↗ Source 4

9.2.1                       Stability   Studies
                                       Stability                          studies                        were                       conducted                       to                        support                      the                        shelf                  life                   unopened                        and
                                       reconstituted                material                   for          the             AD VIA             Centaur                ThCG               MCMs               to             ensure            that                  it
                                       maintains       optimal           product          performance           throughout      the          established      shelf-life.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Treat these as documented evidence themes in this case, including any limitations or negative statements. Ask which protocols, design inputs and acceptance rationale would be justified for your product; these excerpts are not a mandatory test panel.

Extraction selection and limits

Select observed whole-line section headings or explicit colon-delimited inline labels on readable PDF pages, including the explicitly documented heading-spacing variants in this parser version. Preserve the original heading, character ranges and layout; do not repair excerpt text. Exclude letter boilerplate and uncertain pages. Stop at observed table headings; do not infer table columns or scalar results from layout text. Multi-column or suspicious split-numeric excerpts are excluded until reviewed alternate extraction is available. Original layout records remain retained; any alternate text has its own extractor-version locator and requires original-page review. For each dimension, prefer usable versioned alternate text where available, selecting its longest usable excerpt; otherwise select the longest usable original-layout excerpt. Ties preserve source order. Bounded to 64 PDF pages and 3,500 characters per section. This is a selection, not a complete dossier analysis.

Excluded extraction items: {}.

Known facts and deciding inputs

Known context: US. Confirm the organisation’s role, relevant activities and markets against the cited criteria.

Source factRecorded valueWhat to check
510(k) identifierK140505 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Generic device categoryADVIA CENTAUR VITAMIN B12 MASTER CURVE MATERIAL, TOTAL HCG MASTER CURVE MATERIAL, AND TESTOSTERONE MASTER CURVE MATERIAL [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded applicantSiemens Healthcare Diagnostics, Inc. [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
FDA product codeJJX [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Decision date2014-03-31 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded decision codeSESE [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Submission typeAbbreviated [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Receipt date2014-02-27 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.

Prepare a differences and evidence worksheet

Use this checklist to gather your business or product details before speaking with a specialist. The items below explain what to record and suggest useful supporting documents. You can add your own answers in the editable project brief.

  1. Indications and users — what differs in our product?

    Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

    Useful evidence: Our proposed indication, user/population and use environment beside this exact recorded indication.

  2. Design and operating principle — what differs in our product?

    Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

    Useful evidence: Design description, materials/components, accessory list and a differences matrix.

  3. Non-clinical evidence actually described — what differs in our product?

    Treat these as documented evidence themes in this case, including any limitations or negative statements. Ask which protocols, design inputs and acceptance rationale would be justified for your product; these excerpts are not a mandatory test panel.

    Useful evidence: Existing protocols/results and design-specific evidence gaps, with standard editions and scope reviewed separately.

Work packages and dependencies

What needs to happen first

Questions for providers

Sources and data dates

Read the official document in context. The audit details identify the precise locators and preserved versions used for this page.

FDA openFDA — 510(k) decision records ↗

2026-10-05 · retrieved 2026-10-06

Audit details: precise locators and snapshot identifiers

Source key D01 · snapshot 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002

  • [1] device-510k-0001-of-0001.json:results[158298] · record 0f34f688b47b45e7a36f9e4bdf6f60a76ac7d808df91a6c9008837d3950f7f66
  • [5] Complete results array / fda-decision-context:K140505 · record whole dataset partition

FDA 510(k) summary — K140505 ↗

Thu, 10 Apr 2014 14:16:16 GMT · retrieved 2026-10-07

Audit details: precise locators and snapshot identifiers

Source key D02 · snapshot a7744220d2b6415b30d43e91da177976ac76fd135319c0d748c187af11a70b45

  • [2] PDF page 2 · record 54e4dc6bd6b5e0b219a6e8d67f9a3da718eece4806c1a936b883eb6a81acd422
  • [3] PDF page 1 · record 2acbbed96df48e5e7ca460b42c19e897cc427985457dc4cc2ac63048d0f9251d
  • [4] PDF page 9 · record ee397001a27da047b949e6b56f3f9cde72c7738ca55d2cd9932fef03450defc6

Prepare an editable project brief

Confirm the facts, scope and contact preference before sharing your project. Preparing this page sends no provider outreach.

Choose work packages to discuss

Compare FDA 510(k) Submission Services

Packaging + Shelf-life + Distribution Testing